Business Standard

Covid-19 crisis: Made-in-India remdesivir may come by end of June

Currently, the drug is allowed for "restricted emergency use" on severely ill hospitalised Covid patients in India.

remdesivir, coronavirus
Premium

After Gilead’s repurposed drug came into the limelight, the US firm signed licence agreements with Indian manufacturers around mid-May to make and sell the drug in India and other countries.

Sohini Das Mumbai
Gilead’s remdesivir, the only drug with an emergency use authorisation to treat Covid-19 in the US, is expected to be widely available in the Indian market by the end of this month, sources in the know said. The drug may reduce the average time of hospital stay for Covid patients and improve their recovery time.

Currently, the drug is allowed for “restricted emergency use” on severely ill hospitalised Covid patients in India. The antiviral drug may cost around Rs 55,000 for an 11-dose course, or Rs 5,000 per injection — much less than the price of imports from Bangladesh. Domestic pharmaceutical

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 19 2020 | 2:02 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com